Pfizer’ lung cancer drug gets conditional approval from European health regulatory authority as announced by Pfizer Inc. Xalkori (crizotinib) is used for the treatment of advanced non-small cell lung cancer in patients with a specific genetic mutation.
“In the field of metastatic non-small cell lung cancer, XALKORI represents a major advancement. It brings to the patients with ALK-translocated tumors an oral compound that can achieve tumor shrinkage and delay disease progression,” said Dr. Jean-Charles Soria, professor of Medicine and Medical Oncology at South-Paris University and cancer specialist at Institut Gustave Roussy, France.
This approval is conditional so Pfizer has to submit data from a recent successful clinical trial to EU.
Today’s approval is a significant milestone for adults with ALK-positive advanced NSCLC in Europe,” said Dr. Andreas Penk, president of Pfizer Oncology Europe. “XALKORI is a first-in-class medicine and demonstrates Pfizer’s commitment to targeting specific molecular abnormalities and providing the right treatment to the right patient at the right time.”
Xalkori inhibits growth and survival of tumor cells by inhibiting ALK fusion protein that is necessary for the survival of cancerous cells.
Read full article here.
Source: Pfizer News Release